Myriad Genetics Welcomes New Board Member Mark S. Davis
Myriad Genetics, Inc. (NASDAQ: MYGN), renowned for its contributions to genetic testing and precision medicine, has recently made an exciting announcement. The company has elected Mark S. Davis to join its Board of Directors, thereby expanding its board from eight to nine members.
Mark S. Davis: A Seasoned Professional
Mark S. Davis currently serves as the Senior Relationship and Growth Advisor at Cross Country Consulting. Prior to this role, he had a notable career at Deloitte & Touche LLP, spanning nearly four decades until September 2024. During his tenure there, he excelled in various leadership positions, including Audit Partner and National Managing Partner of Deloitte Private Enterprises. Additionally, he was the Managing Partner of the Long Island office.
In 2024, Davis also took a seat on the board of directors of Yext, Inc., where he actively participates as a director and member of the audit committee. Furthermore, he contributes to the advisory board of NYU-Winthrop Hospital and holds a position on the Board of Trustees at Adelphi University, where he is involved in both the finance and investment committee and the audit committee. Davis earned his Bachelor of Business Administration from Adelphi University and is a certified public accountant.
Impact on Myriad Genetics
Louise Phanstiel, the Chair of Myriad Genetics' Board, expressed excitement about Davis's addition, emphasizing his extensive knowledge in financial accounting and public company reporting. She stated that his experience will be invaluable in shaping the company's future direction and enhancing long-term shareholder value. Phanstiel highlighted, “Mark brings a wealth of knowledge and experience… We believe that Mark’s insights will help Myriad Genetics shape our future direction and contribute to generating long-term shareholder value.”
Davis himself shared his enthusiasm, stating that he is inspired by Myriad Genetics' dedication to improving patient care and the healthcare landscape. He looks forward to collaborating with the board and leadership team to promote genetic insights that can lead to meaningful health solutions for patients. His commitment includes driving shareholder value through innovative strategies in genetic testing and precision medicine.
About Myriad Genetics
Myriad Genetics is at the forefront of genetic testing and precision medicine, dedicated to enhancing health and well-being. The company develops a wide range of genetic tests aimed at evaluating the risk of diseases and guiding treatment decisions across various medical fields. Their innovative solutions have the potential to significantly improve patient care and reduce healthcare costs. To learn more about their offerings, interested parties are encouraged to visit www.myriad.com.
Frequently Asked Questions
What is the role of Mark S. Davis at Myriad Genetics?
Mark S. Davis has been elected to the Board of Directors of Myriad Genetics and will also serve on its Audit and Finance Committee.
What prior experience does Mark S. Davis bring?
Davis has a rich background from Deloitte & Touche LLP, where he held various senior roles, including Audit Partner and National Managing Partner.
How does Myriad Genetics benefit from Mark S. Davis's election?
His extensive expertise in financial accounting and public company reporting is expected to enhance the company's strategic direction and generate long-term shareholder value.
What is the mission of Myriad Genetics?
Myriad Genetics aims to improve health and well-being by providing genetic testing that aids in disease risk assessment and treatment decision-making.
How can I contact Myriad Genetics for investor relations?
For inquiries, investors can reach out to Matt Scalo at (801) 584-3532 or via email at IR@myriad.com.
